Brief: uniQure Announces Dosing Of First Patient In Phase I/II Clinical Trial Of AMT-162 For The Treatment SOD1-AlS
15/10/2024 13:12
Oct 15 (Reuters) - Uniqure NV UQ1.F :
* UNIQURE ANNOUNCES DOSING OF FIRST PATIENT IN PHASE I/II
CLINICAL
TRIAL OF AMT-162 FOR THE TREATMENT SOD1-ALS
Source text for Eikon: ID:nGNX8BtQYM
Further company coverage: UQ1.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal